Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy (AVATAR)
Anticancer drugs can lead to various adverse events. This study analyses reports of adverse events for treatment including Anatomical Therapeutic Chemical (ATC) classification L (antineoplastic agents, endocrine therapy, immunostimulants, and immunosuppressants drugs) in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).
Cancer
DRUG: Antineoplastic and Immunomodulating Agents
Adverse events of antineoplastic and immunomodulating agents, Identification and report of adverse event of antineoplastic and immunomodulating agents. The research could include the report with SOC, HGLT, HLT, or PT MedDRA terms, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025
Causality assessment of reported adverse events according to the WHO system, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025|Description of the type of adverse event depending on the category of antineoplastic and immunomodulating agents, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025|Description of the time from anticancer drug initiation and the occurrence of the adverse event, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025|Description of the drug-drug interactions associated with adverse events, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025|Description of the cancer for which the incriminated drugs have been prescribed, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025|Description of the population of patients having adverse event, Case reported in the World Health Organization (WHO) of individual safety case reports to January 1st 2025
The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of adverse events following treatment with antineoplastic agents, endocrine therapy, immunostimulants or immunosuppressants drugs.